Apar Kishor Ganti, MD

Articles by Apar Kishor Ganti, MD

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

ByClayton K. Oakley, DO, MS, MA,Amulya Yellala, MD,Sunil Tulpule, MD,Robin High, MA,Apar Kishor Ganti, MD,Alissa S. Marr, MD

December 5th 2024

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.

Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer

ByPoppy Elvira Deviany, MPH,Apar Kishor Ganti, MD,K.M. Monirul Islam, MD, PhD

March 16th 2021

Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.

Latest Updated Articles

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
Published: October 30th 2025 | Updated:
Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer
Published: March 16th 2021 | Updated:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials
Published: December 5th 2024 | Updated:

Apar Kishor Ganti, MD

Articles by Apar Kishor Ganti, MD

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC

Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer

Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC

Frontline Giredestrant Displays IDFS Improvement vs SOC ET in ER+/HER2– BC

Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma